---
title: "Sartorius Issues New Mid-term Financial Targets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279380203.md"
description: "Sartorius has set new mid-term financial targets, anticipating its addressable markets to grow by 7-9% annually. The company aims to outpace this growth by 100-200 basis points, projecting organic sales revenue growth of 8-11% per year from 2027 onwards. Additionally, Sartorius expects its underlying EBITDA margin to increase by 50-75 basis points annually. The focus will be on strengthening core business areas and developing emerging sectors such as advanced therapy solutions and analytical technologies. Sartorius shares recently traded at 209.00 euros, down 0.33%."
datetime: "2026-03-17T06:47:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279380203.md)
  - [en](https://longbridge.com/en/news/279380203.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279380203.md)
---

# Sartorius Issues New Mid-term Financial Targets

Add  as your preferred news source on Google

 Add Now

Sartorius said, based on its assessment of future market development, the company expects its addressable markets to grow at a rate of approximately 7 to 9 percent per year over the medium term. Against this backdrop, Sartorius introduced a new medium-term ambition for the period from 2027 onwards. Management expects the company to consistently outgrow its addressable markets by around 100 to 200 basis points per year leading to an organic sales revenue growth in constant currencies of 8 to 11 percent per year at group level. Also, underlying EBITDA margin at group level is supposed to grow by approximately 50 to 75 basis points per year.

The company aims to strengthen its core business by reinforcing its leadership positions in mission-critical applications in process intensification, single-use technologies and cell analytics. Sartorius plans to further develop select emerging businesses, including advanced therapy solutions, advanced cell models, process analytical technologies and analytical characterization and quality control platforms.

At last close, Sartorius shares were trading at 209.00 euros, down 0.33%.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [SRT.DE](https://longbridge.com/en/quote/SRT.DE.md)
- [BIO.DE](https://longbridge.com/en/quote/BIO.DE.md)

## Related News & Research

- [Goldman Sachs Remains a Hold on Sartorius (0NIR)](https://longbridge.com/en/news/284184850.md)
- [J.P. Morgan Sticks to Their Buy Rating for Sartorius (0NIR)](https://longbridge.com/en/news/283809636.md)
- [Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach | TLX Stock News](https://longbridge.com/en/news/284280065.md)
- [Merck KGaA and Remepy join forces to develop combo drug-digital therapies](https://longbridge.com/en/news/284400944.md)
- [ESCMID Global 2026: Adibelivir emerges as potential disease-modifying therapy for HSV](https://longbridge.com/en/news/283881368.md)